|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Herein, the authors describe the prevalence, clinical features, and outcomes associated with HER2 mutations in 1007 patients in the Lung Cancer Mutation Consortium (LCMC).
|
28743157 |
2017 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Why are mutation rates in epidermal growth factor receptor (EGFR) and erb-b2 receptor tyrosine kinase 2 (ERBB2) higher in lung cancer from never smokers than that from smokers?Question 62.
|
28974261 |
2017 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2 is a major proliferative driver in lung cancer.
|
28063177 |
2017 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
An ERBB2 exon 20 insertion-mutated lung cancer cell line had a 50% inhibitory concentration in response to afatinib that was higher than the reported plasma concentration of afatinib, 40 mg daily.
|
26964772 |
2016 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Combination of In Silico Analysis and In Vitro Assay to Investigate Drug Response to Human Epidermal Growth Factor Receptor 2 Mutations in Lung Cancer.
|
27491651 |
2016 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
In addition, these effects were confirmed in vivo by using a xenograft mouse model of HER2-altered lung cancer cells.
|
26545934 |
2016 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
The molecular target drugs for lung cancer with anaplastic lymphoma kinase (ALK) gene translocation (the fusion gene, EML4-ALK) was approved, and those targeting lung cancers addicted ROS1, RET, and HER2 have been under development.
|
27686809 |
2016 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2-positive lung cancer may not be an adequate term, and patient cohorts for the study of HER2-targeted agents should be defined by the specific HER2 alteration present.
|
26723242 |
2016 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
We present a patient with HER2 mutant lung cancer with a 12 base pair insertion YVMA (p.A775_G776insYVMA), who had a long natural history and durable partial response to afatinib.
|
26559459 |
2015 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
After MRI diagnosis, breast and lung cancer brain metastases were successfully treated with similar tumor-targeted nanoconjugates carrying molecular inhibitors of EGFR or HER2 instead of imaging contrast agent.
|
25906400 |
2015 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Dacomitinib (PF-00299804) is a small-molecule inhibitor of the tyrosine kinases human epidermal growth factor receptor-1 (HER1; epidermal growth factor receptor, EGFR), HER2, and HER4 currently being developed for the treatment of lung cancer with sensitizing mutations in EGFR or refractory to EGFR-directed treatment.
|
26048096 |
2015 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
EGFR and HER2 mutations and ALK rearrangement are known to be related to lung cancer in never-smokers, while KRAS, BRAF and PIK3CA mutations are typically observed among smokers.
|
25745045 |
2015 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome.
|
26678909 |
2015 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Examples of these molecularly targeted biomarker therapies are: tyrosine kinase inhibitors in chronic myeloid leukemia and gastrointestinal tumors; anaplastic lymphoma kinase (ALK) inhibitors in lung cancer with EML4-ALk fusion; HER2/neu blockage in HER2/neu-positive breast cancer; and epidermal growth factor receptors (EGFR) inhibition in EGFR-mutated lung cancer.
|
25468140 |
2015 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
A missense mutation, L755P, in the HER2 kinase domain has been involved in lung cancer in humans and exhibits reduced response to lapatinib therapy.
|
25620423 |
2015 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Targeting BCR-ABL in chronic myeloid leukemia (CML) or HER2 in breast cancer has led to practice-changing clinical benefits, while promising therapeutic responses have been achieved by precision medicine approaches in EGFR mutant lung cancer, colorectal cancer and BRAF mutant melanoma.
|
26615134 |
2015 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Other driver biomarkers in lung cancer (point mutations and rearrangements in specific genes including Her2, BRAF, NUT, MET, ROS1, DDR2, FGFR1, KRAS, and PTEN) might potentially provide additional information for clinical decision making.
|
24420742 |
2014 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
It eases the sample size bottleneck; evaluations on simulated data and lung cancer-specific ERBB2 and MAPK signaling pathways, with varying number of samples, evince the merit in handling high exon to sample size ratio datasets.
|
25034693 |
2014 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Ectopic expression of CD74-NRG1 in lung cancer cell lines expressing ERBB2 and ERBB3 activated ERBB3 and the PI3K-AKT pathway, and led to increased colony formation in soft agar.
|
24469108 |
2014 |
|
Carcinoma of lung
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Activity of the EGFR-HER2 dual inhibitor afatinib in EGFR-mutant lung cancer patients with acquired resistance to reversible EGFR tyrosine kinase inhibitors.
|
25242668 |
2014 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
On the basis of preclinical data suggesting synergy of HER2 inhibition and mTOR inhibition in breast and lung cancer models, we conducted a phase I combination study of neratinib, a small-molecule irreversible pan-HER tyrosine kinase inhibitor, and temsirolimus, an mTOR inhibitor, in patients with advanced solid tumors.
|
24323026 |
2014 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Secretory phospholipase A2-IIa upregulates HER/HER2-elicited signaling in lung cancer cells.
|
24913497 |
2014 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
HER2 and lung cancer.
|
24134423 |
2013 |
|
Carcinoma of lung
|
0.400 |
Biomarker
|
disease |
BEFREE |
Following the identification of HER2-activating events in the most recent lung carcinoma and in circulating tumor cells, we treated the reminiscent metastatic lesions with a lapatinib-based therapy.
|
23950206 |
2013 |
|
Carcinoma of lung
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Delivery of chemically stabilized anti-mCRP siRNAs using cationic lipoplexes, AtuPLEXes, to HER2-over-expressing BT474, SK-BR-3 (breast), SKOV3 (ovarian) and Calu-3 (lung) cancer cells reduced mCRPs expression by 85-95%.
|
23474221 |
2013 |